Results 41 to 50 of about 301,643 (264)

On TRacK With Larotrectinib in a Neonate With a Giant Congenital ETV6::NTRK3 Fusion‐Positive Infantile Fibrosarcoma of the Head and Neck

Head &Neck, EarlyView.
ABSTRACT Background Infantile fibrosarcoma (IFS) is a rare pediatric tumor of intermediate malignancy with high local aggressiveness that typically presents in young infants. Its occurrence in the head and neck region is rare. Complete non‐mutilating surgical resection is often not possible, requiring multimodal treatment.
Teresa M. Cardesa‐Salzmann, Monika Sparber‐Sauer, Peter Hingst, Andreas Erbersdobler, Bjoern Schneider, Maja Hühns, Andre Jakob, Friederike Terpe, Christian Spang, Dorothea Stalmann, Claudia Bierwirth, Christina Hauenstein, Stefanie Märzheuser, Manfred Ballmann, Carl Friedrich Classen   +14 more
wiley   +1 more source

Laparoscopic nephrectomy in a hemophilia B patient [PDF]

Central European Journal of Urology, 2016
Surgery in patients with hemophilia is a serious challenge. It requires a comprehensive approach, as well as careful postoperative monitoring. We present here the first case of a transperitoneal laparoscopic radical nephrectomy (TLRN) for renal cell carcinoma, of the clear-cell type, performed in a hemophilia B patient.
Gajda, Slawomir, Szopiński, Tomasz, Szczepanik, Andrzej B., Sosnowski, Roman, Szczepanik, Anna M.   +4 more
openaire   +3 more sources

Pharmacokinetic Study of Recombinant Human Factor IX in Previously Treated Patients with Hemophilia B in Taiwan

Journal of the Formosan Medical Association, 2007
The pharmacokinetic (PK) study of recombinant human factor IX (rFIX) has been done in patients with hemophilia B in areas other than Taiwan. However, wide patient-related variability in recovery is noted and there is no PK study of rFIX in Taiwanese ...
Hsiu-Hao Chang, Yung-Li Yang, Mei-Hua Hung, Woei Tsay, Ming-Ching Shen   +4 more
doaj   +1 more source

Origin of Swedish hemophilia B mutations [PDF]

Journal of Thrombosis and Haemostasis, 2013
More than 1100 mutations that cause hemophilia B (HB) have been identified. At the same time, specific F9 mutations are present at high frequencies in certain populations, which raise questions about the origin of HB mutations.To describe the mutation spectrum of all HB families in Sweden and investigate if mutations appearing in several families are ...
Christina Lind-Halldén, Christer Halldén, Annika Mårtensson, Daniel Nilsson, Daniel Nilsson, Torbjörn Säll, Rolf Ljung, Annika C. Lidén   +7 more
openaire   +3 more sources

Investigating the role of SARM1 in central nervous system

Ibrain, EarlyView.
Sterile‐α and Toll/interleukin 1 receptor (TIR) motif‐containing protein 1 (SARM1) is a pivotal molecule that has garnered extensive attention in neuroscience. As an intracellular molecule, SARM1 possesses various crucial biological functions in the nervous system.
Junjie Wang, Yuhang Shi, Jinglei Tian, Liming Tang, Fang Cao   +4 more
wiley   +1 more source

The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B

Blood Advances, 2018
: Data are needed on minimal factor activity (FA) levels required to prevent bleeding in hemophilia. We aimed to evaluate associations between hemophilia type and FA level and joint bleeding and orthopedic procedures using longitudinal data.
J. Michael Soucie, Paul E. Monahan, Roshni Kulkarni, Barbara A. Konkle, Marshall A. Mazepa   +4 more
doaj  

Why should hemophilia B be milder than hemophilia A?

Haematologica, 2016
We read with interest the report by Melchiorre et al .[1][1] on the milder clinical parameters in hemophilia B as compared to hemophilia A. The single most important factor which contributes to the severity of hemophilia is the nature of mutations.
Shrimati Shetty, Kanjaksha Ghosh
openaire   +4 more sources

A new era for hemophilia B treatment [PDF]

Blood, 2016
In this issue of Blood, Santagostino et al, in their phase 3 study, demonstrate efficacy and safety of recombinant fusion protein linking coagulation factor IX (FIX) with albumin (rIX-FP) which, along with the other 2 extended half-life FIX products, heralds a new era for the treatment of hemophilia B.
Rebecca Kruse-Jarres, Jason A. Taylor
openaire   +3 more sources

Efanesoctocog Alfa Population Pharmacokinetics and Repeated Time‐To‐Event Analysis of Bleeds in Adults, Adolescents, and Children with Severe Hemophilia A

The Journal of Clinical Pharmacology, EarlyView.
Abstract Efanesoctocog alfa is a first‐in‐class high‐sustained factor VIII (HSF) replacement therapy for treatment of hemophilia A. This article presents population pharmacokinetics (PopPK) of efanesoctocog alfa and repeated time‐to‐event (RTTE) analysis of bleeding episodes in adults/adolescents (≥12 years of age) and children (<12 years).
Nancy Wong, Pratik Bhagunde, Joakim Nyberg, Suresh Katragadda, Marek Demissie, Annemieke Willemze, Craig Benson, Sreeraj Macha   +7 more
wiley   +1 more source

Could PTH/Ca Ratio Serve as a New Marker for Evaluating Bone Metabolism in Hemophilia Patients?

Diagnostics
Background/Objectives: Low bone mineral density (BMD) is common in hemophilia patients. Identifying high-risk patients for low BMD early is essential to prevent complications and reduce morbidity.
Tuba Ersal, Fazıl Çağrı Hunutlu, Vildan Gürsoy, Ezel Elgün, Şeyma Yavuz, İpek Dal Akkuş, İlayda Baş, Vildan Özkocaman, Fahir Özkalemkaş   +8 more
doaj   +1 more source